When was SeQure Dx founded?

SeQure Dx was founded in 2020 and raised its 1st funding round 1 year after it was founded.

Where is SeQure Dx located?

SeQure Dx is headquartered in Waltham, United States.

How many employees does SeQure Dx have?

As of Aug 31, 2026, the latest employee count at SeQure Dx is 2.

Is SeQure Dx a funded company?

SeQure Dx is a funded company, having raised a total of $22.3M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Aug 03, 2021.

When was the latest funding round of SeQure Dx?

SeQure Dx's latest funding was a $***** Series A round on Nov 21, 2023, with participation from 0 investor. Its primary sector is Genomics. In United States, the Genomics sector has seen $2.39B in funding in 2026 to date.

Where does SeQure Dx rank among its competitors?

SeQure Dx ranks 136th amongst 358 active competitors, of which 122 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was GenSight Biologics, which secured $1.96M in Mar, 2026.

Who are the top competitors of SeQure Dx?

SeQure Dx's top competitors include MedGenome, Geneoscopy and Caris Life Sciences. Among them, GenSight Biologics secured the most recent funding round in March, 2026.

SeQure Dx - 2026 Company Profile, Funding & Competitors

Company Details

Developer of personalized diagnostics for gene-editing therapies. The company's technologies GUIDE-seq and ONE-seq enable the identification and confirmation of target sites for developing gene therapies.

Website: sequre-dx.com
Email ID: *****@sequre-dx.com

Key Metrics

Founded Year

2020

Location

Waltham, United States

Stage

Acquired

Total Funding

$22.3M in 3 rounds

Latest Funding Round

Series A, Nov 21, 2023, $*****

Investors

RiverVest Venture Partners & 6 more

Ranked

136^th among 358 active competitors

Employee Count

2 as on Aug 31, 2026

Similar Companies

MedGenome & 506 more

Exit Details

Acquired by MaxCyte (Jan 30, 2025)

View SeQure Dx's full profile

SeQure Dx got acquired by MaxCyte on Jan 30, 2025.

Click here to take a look at SeQure Dx's acquisition in detail

SeQure Dx has raised a total funding of $22.3M over 3 rounds. Its first funding round was on Aug 03, 2021. SeQure Dx has 7 institutional investors.

Here is the list of recent funding rounds of SeQure Dx:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 21, 2023	2055551	Series A	4003242	3614826	6982806	6900816
Jun 22, 2023	3936774	Series A	2167704	1694200	5615213	3759660
Aug 03, 2021	8904355	Series A	9898698	4941318	RiverVest Venture Partners & 1 more	Digitalis Ventures & 4 more

Access funding benchmarks and valuations. Sign up today!

View details of SeQure Dx's funding rounds and investors

SeQure Dx's employee count trend

SeQure Dx has 2 employees as of Aug 26. Here is SeQure Dx's employee count trend over the years:

Uncover SeQure Dx's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of SeQure Dx include MedGenome, Geneoscopy and Caris Life Sciences. Here is the list of Top 10 competitors of SeQure Dx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	MedGenome 2013, Bengaluru (India), Series E	Provider of DNA sequencing, bioinformatics, and multiomics services	$264M	Novo Holdings, Peak XV Partners & 30 others	70/100
2nd	Geneoscopy 2015, St. Louis (United States), Series C	Developer of non-invasive biomarker tests for colorectal cancer	$219M	LightChain Capital, Cultivation Capital & 18 others	69/100
3rd	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Coatue & 19 others	67/100
4th	Intellia Therapeutics 2014, Cambridge (United States), Public	Developer of therapeutics based on CRISPR/Cas9 technology for multiple diseases	$85M	Atlas Venture, Novartis & 10 others	66/100
5th	Deep Genomics 2014, Toronto (Canada), Series C	AI-powered platform for RNA biology to accelerate genetic therapy discovery	$238M	SoftBank Vision Fund, True Ventures & 16 others	62/100
6th	UniQure 1998, Amsterdam (Netherlands), Public	Developer of gene-based therapies for patients with genetic or acquired diseases	$111M	Gilde Healthcare, Advent Life Sciences & 11 others	62/100
7th	Regulus Therapeutics 2007, San Diego (United States), Acquired	Innovative medicines company reimagining medicine to improve and extend people’s lives	$35M	Ionis Pharmaceuticals, Alnylam & 9 others	62/100
8th	Precipio Diagnostics 1997, New Haven (United States), Public	Provider of cancer diagnostics and second opinion tools	$800K	Enhanced Capital, Connecticut Innovations ... & 3 others	61/100
9th	GenSight Biologics 2011, Paris (France), Public	Developer of viral vector-based gene therapies for retinal neurodegenerative diseases	$76.6M	Perceptive Advisors, Fidelity Investments ... & 17 others	61/100
10th	Cleveland Diagnostics 2013, Cleveland (United States), Series E	Developer of diagnostics technology to detect cancer in early stage	$111M	LYFE Capital, Novo Holdings & 5 others	60/100
136th	SeQure Dx 2020, Waltham (United States), Acquired	Developer of personalized diagnostics for gene-editing therapies	$22.3M	RiverVest Venture Partners, Digitalis Ventures ... & 5 others	36/100